Key Highlights
- Shares are up 19.81% in pre-market trading to $41.85, after closing up 1.51% at $34.93 the prior session.
- The PHocus study met its primary endpoint, showing a statistically significant, placebo-adjusted 56.3% reduction in pulmonary vascular resistance at Week 16, the largest such reduction reported in a randomized pulmonary hypertension trial to date.
- The study also showed meaningful improvements in six-minute walk distance and NT-proBNP through Week 24.
- Results support initiation of the Phase 3 PHrontier study, which is now enrolling patients for a potential first-in-class, once-daily inhaled therapy.
Roivant Sciences Surges on Positive Phase 2 Trial Results
Roivant Sciences (NASDAQ:ROIV) shares are up 19.81% in pre-market trading to $41.85, after its Pulmovant Subsidiary announced positive Phase 2 PHocus results for mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, a condition with limited treatment Options and high unmet need. The stock had closed up 1.51% at $34.93 the prior session, and today's pre-market move puts shares well above their prior 52-week high of $37.97.
Roivant Sciences is a London-based, commercial-stage biopharmaceutical company founded in 2014 that operates a distinctive Vant model, creating nimble subsidiaries to develop and commercialize individual drug candidates across a broad range of therapeutic areas. Its pipeline spans immunology, dermatology, oncology, hematology, and rare diseases, featuring Assets such as the approved topical Vtama for psoriasis and atopic dermatitis, along with clinical-stage candidates like batoclimab, brepocitinib, IMVT-1402, and mosliciguat targeting conditions including thyroid eye disease, myasthenia gravis, sarcoidosis, and pulmonary hypertension.
PHocus Study Delivers Largest PVR Reduction in a Randomized PH Trial
The PHocus study met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance of 56.3% at Week 16, which the company said represents the largest such reduction reported in a randomized pulmonary hypertension trial to date. The study also showed meaningful improvements in six-minute walk distance and NT-proBNP, a biomarker of cardiac strain, through Week 24.
The data was presented at the ERS International Congress and discussed on an investor call, where management said the results support initiation of the Phase 3 PHrontier study, which is now enrolling patients. Pulmonary hypertension associated with interstitial lung disease is a serious condition with limited treatment options, and the company is positioning mosliciguat as a potential first-in-class, once-daily inhaled therapy.
What This Means for Investors
Today's rally reflects genuine clinical validation rather than a speculative move, with the 56.3% reduction in pulmonary vascular resistance representing a large effect size relative to prior trials in this patient population. The confirmatory improvements in functional capacity, via six-minute walk distance, and cardiac biomarkers strengthen the case that the drug is having a meaningful physiological impact rather than moving a single surrogate marker in isolation. Pulmonary hypertension associated with interstitial lung disease has historically been difficult to treat, with limited approved options and significant unmet need, which raises the commercial stakes of a positive readout in this population.
With the Phase 3 PHrontier study now enrolling, the next major catalyst is further out, and investors will need to weigh today's re-rating against the execution risk inherent in any late-stage trial, along with the multi-year timeline before a potential approval and commercial launch. The scale of today's move also reflects how thinly covered and modestly valued the stock was heading into this data, meaning a genuinely positive surprise can produce an outsized reaction relative to companies with more established, closely tracked pipelines.






Please wait processing your request...